NNVC -- NanoViricides Achieving Recognition in the Biotech and Nanotech Industries for Its Nanotechnology-based Anti-viral Therapies
WEST HAVEN, Conn., Jul 18, 2006 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced today that two of its senior executives, Dr. Anil Diwan, Chairman and President, and Dr. Eugene Seymour, CEO, have been invited to lecture and present the NanoViricides at five different conferences over the next five months. Dr. Diwan will be presenting at four nanotechnology conferences in the United States and Dr. Seymour at an international nanomedicine conference in London.
Dr. Anil Diwan, Chairman and President, said, "For many years it has been believed that the technologies inherent in the nanomedicine approach would result in far superior drugs than anything presently existing. We feel that we're at the forefront in this arena. We believe that with the first viruses we have targeted, avian flu (H5N1) and common influenza (H1N1), we have achieved results in the preclinical studies far superior to any existing drug. NanoViricides, Inc. is awaiting permission from the appropriate institutions to release the results."
In other news, the company announced that they are working with their auditors to complete the June 30, 2006 audit, and the company expects the company's financials to be released over the coming weeks. The company aims to file with the SEC to become a fully reporting company after the audit is completed.
Dr. Eugene Seymour, CEO, further added, "We believe that our business plan is sound. Just yesterday the Financial Times had as its lead story that Citigroup is expanding its research and its Director of Investment Research said 'the most important task for analysts was to produce quality research, such as thematic reports on bird flu ...'". Dr Seymour continued, "NanoViricides at this time is strong. We have over $2,000,000 cash on hand. We have a strong drug pipeline with industry-leading drugs against highly pathogenic bird flu and common influenza in preclinical studies, and an anti-rabies drug in development. I see no technological barriers to accomplish our stated goals to develop additional new drugs in the areas of HIV, Hepatitis C as well as other viral infections in 2007 and beyond."
About NanoViricides - nanoviricides.com
SOURCE: NanoViricides, Inc.
CONTACT: NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo@nanoviricides.com
. |
